BTPNF yields 25317.05% · JNJ yields 2.13%● Live data
📍 BTPNF pulled ahead of the other in Year 1
Combined, BTPNF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BTPNF + JNJ for your $10,000?
PT Bank BTPN Tbk provides various banking products and services primarily in Indonesia. It operates through five segments: Retail; Micro, Small & Medium Enterprises; Funding and Treasury; Corporate; and Sharia. The company offers savings and current account; term, flexi, and time deposits; and working capital and investment, bilateral and syndication, term, demand, green, pension, active employee, and student Loan; sustainability linked loan project/structured financing, overdraft, asset-based and rural bank financing, and supply chain financing; and credit cards. It also provides bancassurance and investment products, such as mutual fund and government bonds; Sharia banking services; import LC issuance/ import bill negotiation, export LC advising/confirmation/export bill collection, documentary collection, trust receipt/trade loan, structured trade finance, receivable purchase, and bank guarantee services; and liquidity management, internet and mobile banking, and collections payment services. In addition, the company offers treasury services, such as foreign exchange, derivatives, money market, and fixed income. As of December 31, 2021, it operated 82 branches, 349 subbranches, 224 and ATMs and TCRs. The company was founded in 1958 and is headquartered in Jakarta, Indonesia. PT Bank BTPN Tbk operates as a subsidiary of Sumitomo Mitsui Banking Corporation.
Full BTPNF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.